Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Sep 1, 2009

Premium

Michael Snyder has moved from Yale University to Stanford University, where he has become chair of the Department of Genetics. He will also lead a new Center of Genomics and Personalized Medicine, which will bundle school and university efforts in genomics and their application to diagnosing and managing human disease.

At Yale, which he joined as a faculty member in 1986, Snyder was most recently a professor of biology and director of the Yale Center for Genomics and Proteomics. From 1998 until 2004, he was chair of the Department of Molecular, Cellular, and Developmental Biology. Snyder holds a PhD from the California Institute of Technology and did a postdoctoral fellowship at Stanford with Ron Davis in the Department of Biochemistry.


Jim McDonald has joined Oxford Nanopore Technologies as finance director. Previously, he was finance director of MediSense UK, which was later acquired by Abbott Laboratories. Prior to that, he held several positions at Arthur Andersen, both in London and in the US, and before that, he worked as a lawyer for a Denver law firm. He has a legal as well as a financial reporting background.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.